Jay Feingold
Impact in
- Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
-
- Lymphoma Diagnosis and Treatment
Papers in
-
- DNA Repair Mechanisms 4
- Oncology 18
- CAR-T cell therapy research 9
- HER2/EGFR in Cancer Research 6
- Co-authors
- Anna Berkenblit (7 shared papers)Andrew Strahs (6 shared papers)Janice P. Dutcher (4 shared papers)Mehdi Hamadani (18 shared papers)John Radford (15 shared papers)Paolo F. Caimi (16 shared papers)Karin Havenith (8 shared papers)Alexandra Thiele (4 shared papers)
- Journals
- Blood (11 papers)Hematological Oncology (5 papers)Journal of Clinical Oncology (4 papers)Bone Marrow Transplantation (2 papers)Acta Haematologica (2 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Jay Feingold
51 papers receiving 1.7k citations
Jay Feingold's Hit Papers
Peers
Comparison fields: 5 of 77
- Oncology 748
- Pathology and Forensic Medicine 458
- Cancer Research 269
- Pulmonary and Respiratory Medicine 501
- Genetics 143
Countries citing papers authored by Jay Feingold
This map shows the geographic impact of Jay Feingold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Feingold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Feingold more than expected).
Fields of papers citing papers by Jay Feingold
This network shows the impact of papers produced by Jay Feingold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Feingold. The network helps show where Jay Feingold may publish in the future.
Co-authors
The 25 scholars most cited alongside Jay Feingold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 284 |
| 2 | 2009 | 209 | |
| 3 | 2008 | 140 | |
| 4 | 2020 | 132 | |
| 5 | 2007 | 95 | |
| 6 | 2019 | 82 | |
| 7 | 2009 | 75 | |
| 8 | 2021 | 68 | |
| 9 | 1977 | 60 | |
| 10 | 2009 | 47 | |
| 11 | 1999 | 45 | |
| 12 | 1999 | 44 | |
| 13 | 2020 | 42 | |
| 14 | 1985 | 39 | |
| 15 | 2018 | 37 | |
| 16 | 2020 | 31 | |
| 17 | 2000 | 29 | |
| 18 | 2010 | 27 | |
| 19 | 1988 | 19 | |
| 20 | 2001 | 18 |
About Jay Feingold
Jay Feingold is a scholar working on Molecular Biology, Oncology, Pathology and Forensic Medicine, Organic Chemistry and Pulmonary and Respiratory Medicine, having authored 53 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (10 papers), Synthesis and pharmacology of benzodiazepine derivatives (9 papers), CAR-T cell therapy research (9 papers), HER2/EGFR in Cancer Research (6 papers), Renal cell carcinoma treatment (5 papers), Chronic Lymphocytic Leukemia Research (5 papers), DNA Repair Mechanisms (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Oncology (748 citations), Pathology and Forensic Medicine (458 citations), Cancer Research (269 citations), Pulmonary and Respiratory Medicine (501 citations) and Genetics (143 citations). Jay Feingold has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Anna Berkenblit, Andrew Strahs, Janice P. Dutcher, Mehdi Hamadani, John Radford, Paolo F. Caimi, Karin Havenith, Alexandra Thiele, Cezary Szczylik and Gary R. Hudes. Their work appears in journals such as Blood, Hematological Oncology, Journal of Clinical Oncology, Bone Marrow Transplantation and Acta Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.